Every 10-Q that Adicet Bio, Inc. (ACET) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACET and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACET filings page.
Adicet Bio develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Lead candidate prula-cel, a CD20-targeting CAR gamma delta T cell, is in Phase 1 across multiple autoimmune indications, including lupus nephritis and systemic lupus erythematosus, and has FDA Fast Track designations in several settings. The company is preparing a potential pivotal lupus nephritis/SLE trial for the second half of 2026, subject to regulatory clearance, and advancing ADI-212, a PSMA-targeted candidate for metastatic castration-resistant prostate cancer, toward an initial regulatory submission in the third quarter of 2026.
For the quarter ended June 30, 2026, Adicet reported a net loss of $21.4 million, improved from $31.2 million a year earlier, as research and development expense fell to $18.5 million from $28.4 million while general and administrative costs were stable. The six‑month net loss was $41.6 million, with $41.3 million of net cash used in operating activities. Cash and cash equivalents were $33.1 million, short‑term treasury investments were $85.1 million, and restricted cash was $2.9 million as of June 30, 2026. Management states that this liquidity should fund forecasted operating and capital needs for at least 12 months, but the company remains pre‑revenue and expects to rely on future financings and collaborations.
Adicet Bio reported a net loss of $20.2 million for the quarter ended March 31, 2026, narrowing from $28.2 million a year earlier as it reduced operating expenses. Research and development spending fell 23% to $17.5 million, and general and administrative costs declined 42% to $4.1 million, largely from lower headcount and stock-based compensation.
Total assets were $169.4 million, including $36.2 million in cash and cash equivalents and $101.3 million in short-term U.S. Treasury securities, against total liabilities of $29.3 million. Management expects existing cash, cash equivalents and short-term investments to fund operations for at least twelve months.
Adicet continues to focus on prula-cel, its lead allogeneic gamma delta CAR-T candidate for autoimmune diseases, with ongoing Phase 1 trials in lupus nephritis, systemic lupus erythematosus, systemic sclerosis and other indications, and on ADI-212 for metastatic castration-resistant prostate cancer, for which it plans a regulatory filing in the third quarter of 2026.
Adicet Bio (ACET) reported Q3 2025 results with a net loss of $26,856,000 and total operating expenses of $27,952,000 (research and development $22,853,000; general and administrative $5,099,000). Interest income was $1,172,000.
Liquidity remained the key focus. As of September 30, 2025, cash and cash equivalents were $29,099,000 and short‑term U.S. treasury investments were $73,999,000. Net cash used in operating activities for the nine months was $74,337,000. Management states current cash, cash equivalents and short‑term treasuries are expected to fund operations for at least twelve months from issuance.
In October 2025, the company completed an underwritten registered direct offering of 70,001,000 shares at $1.00 and pre‑funded warrants to purchase 10,000,000 shares at $0.9999, generating net proceeds of approximately $74,800,000. ACET transferred its listing to the Nasdaq Capital Market on October 9, 2025 for an additional compliance period under the minimum bid price rule. Shares outstanding were 153,255,581 as of November 3, 2025.